The association of clinicopathological features and survival in colorectal cancer patients with kras mutation status
| Autor: | Ilhan Oztop, Ahmet Ugur Yilmaz, Ilkay Tugba Unek, Necla Demir, Hülya Ellidokuz, Tulay Akman, Yasemin Baskin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Colorectal cancer Kaplan-Meier Estimate Gene mutation medicine.disease_cause lcsh:RC254-282 Proto-Oncogene Proteins p21(ras) Clinicopathological properties KRAS metastatic colorectal cancer prognosis 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Genetic Predisposition to Disease Radiology Nuclear Medicine and imaging neoplasms Genetic Association Studies Aged Aged 80 and over business.industry General Medicine Middle Aged Prognosis medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens digestive system diseases 030220 oncology & carcinogenesis Mutation Mutation (genetic algorithm) Cancer research Clinicopathological features Female 030211 gastroenterology & hepatology KRAS Colorectal Neoplasms business Kras mutation |
| Zdroj: | Journal of Cancer Research and Therapeutics, Vol 12, Iss 1, Pp 96-102 (2016) |
| ISSN: | 1998-4138 0973-1482 |
| Popis: | Background: KRAS mutations have a significant role in the consecutive activation of RAS.RAF.MEK.ERK pathway in colorectal cancer.Approximately 30.35% of sporadic colorectal cancers have KRAS mutation. While the predictive role of KRAS is commonly accepted at the present time, its prognostic role and association with different clinical and histopathological properties are currently unclear and inconsistent. The intent of this study, has been to evaluate the associations between KRAS gene mutations and clinicopathological features and survival times in Turkish colorectal cancer patients. Materials and Methods: In this study, the file records of 115 metastatic colorectal cancer patients who applied to the Department of Medical Oncology between 2000 and 2011 were monitored; data on clinicopathological features and survival times were collected. DNA.sequencing method with PCR amplification from archival paraffin blocks were used for KRAS mutation status analysis. The associations between KRAS mutation status and clinicopathological features and survival times were compared statistically. Results: While a significant association hadbeen determined between KRAS mutation status and tumor localization, there was no determined significant association with other clinicopathological properties. Similarly, there was no association between KRAS mutation status and survival parameters. Conclusions: As a result, the effect of KRAS mutation status on clinicopathological features, survival time and prognosis is unclear. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|